Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05664477 · ClinicalTrials.gov registry record · Phase 2
PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition
A Phase 2 study of Menopause and Cognitive Change, sponsored by Roberta Brinton.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT05664477: Active Phase 2 study of Menopause and Cognitive Change, sponsored by Roberta Brinton.
NCT05664477 is a Phase 2 study of Menopause and Cognitive Change that is active but no longer recruiting, run by Roberta Brinton. The registered enrollment target is 100 participants, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05664477, a Phase 2 study of Menopause and Cognitive Change, is active but no longer recruiting, sponsored by Roberta Brinton.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a proof-of-concept phase 2 clinical trial to investigate the safety and effect of the phytoestrogenic supplement PhytoSERM on regional brain metabolism by fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in peri- and postmenopausal women. The investigators hypothesize that there will be a significant difference between the PhytoSERM group and placebo group in glucose brain metabolism.
Primary Outcome
Regional brain glucose metabolism SUVR
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT PhytoSERM
Study Locations (2)
Arizona
- University of Arizona / Clinical & Translational Sciences Research Center (CATS - Tucson
New York
- The Alzheimer's Prevention Program / Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-01-10 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
What the registry record for NCT05664477 still lists
NCT05664477 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05664477 reports a single indexed study location in Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT05664477 about?
NCT05664477 is a clinical study titled "PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition". This is a proof-of-concept phase 2 clinical trial to investigate the safety and effect of the phytoestrogenic supplement PhytoSERM on regional brain metabolism by fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in peri- and postmenopausal women. The investigators hypothesiz...
What is the current status of trial NCT05664477?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-01-10. Estimated completion is 2027-01-31.
What conditions does trial NCT05664477 study?
This clinical trial studies the following conditions: Menopause, Cognitive Change, Brain Disorder, Metabolic.
What interventions are being tested in trial NCT05664477?
The interventions under investigation include: Placebo (DRUG), PhytoSERM (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05664477?
This trial is sponsored by Roberta Brinton, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05664477 being conducted?
This trial has 2 study locations across Arizona, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05664477's enrollment target sits among peer trials
100 19th of 54 higher than 33 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
Impact of Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
COMPLETED · Phase 2
-
A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI